Vassilis Golfinopoulos

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications

European Organisation for Research and Treatment of Cancer (EORTC) 2025 Program for Early Career Investigators: Advancing Ideas into Clinical Research.

European Organisation for Research and Treatment of Cancer (EORTC) 2025 Program for Early Career Investigators: Advancing Ideas into Clinical Research.

Journal: European journal of cancer (Oxford, England : 1990)
Published: March 13, 2026

European screening platform for EORTC clinical trials in advanced colorectal cancer 'SPECTAcolor'.

European screening platform for EORTC clinical trials in advanced colorectal cancer 'SPECTAcolor'.

Journal: ESMO gastrointestinal oncology
Published: February 06, 2026

ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 10, 2025

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

ESMO adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 10, 2025

Prognostic value of 1D, 2D, and volumetric tumor size increases in recurrent WHO grade 2 and 3 meningiomas: Radiological post-hoc analysis of the EORTC-BTG-1320 trial.

Prognostic value of 1D, 2D, and volumetric tumor size increases in recurrent WHO grade 2 and 3 meningiomas: Radiological post-hoc analysis of the EORTC-BTG-1320 trial.

Journal: Neuro-oncology advances
Published: July 30, 2025

Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.

Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.

Journal: The Lancet. Oncology
Published: July 13, 2025

Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations.

Molecular analysis of adolescent and young adult high grade gliomas in the SPECTA-AYA study: Poorly characterised tumours with frequent germline alterations.

Journal: European journal of cancer (Oxford, England : 1990)
Published: November 30, 2024

Core outcome sets in cancer clinical trials: current status and future opportunities-an EORTC perspective.

Core outcome sets in cancer clinical trials: current status and future opportunities-an EORTC perspective.

Journal: Trials
Published: August 14, 2024

Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.

Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.

Journal: Acta neuropathologica
Published: June 06, 2024

Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.

Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.

Journal: bioRxiv : the preprint server for biology
Published: April 02, 2024

3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.

3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.

Journal: Neuro-oncology
Published: March 07, 2024

Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling.

Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling.

Journal: Nature cancer
Published: February 28, 2024
Showing 1-12 of 53

Last Updated: 09/26/2026